• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.多西他赛/顺铂疗法用于合并高血压/糖尿病的重症肌无力患者
Open Med (Wars). 2017 Dec 2;12:403-408. doi: 10.1515/med-2017-0058. eCollection 2017.
2
Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma.多西他赛联合顺铂化疗对转移性胸腺瘤重症肌无力患者的治疗潜力
Tohoku J Exp Med. 2017 Apr;241(4):281-286. doi: 10.1620/tjem.241.281.
3
Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma.胸腺瘤相关重症肌无力:抗乙酰胆碱受体抗体在胸腺瘤复发风险中的临床特征和预测价值。
Thorac Cancer. 2021 Jan;12(1):106-113. doi: 10.1111/1759-7714.13724. Epub 2020 Nov 3.
4
Robotic thymectomy for thymoma in patients with myasthenia gravis: neurological and oncological outcomes.机器人胸腺切除术治疗重症肌无力患者胸腺瘤:神经和肿瘤学结果。
Eur J Cardiothorac Surg. 2021 Oct 22;60(4):890-895. doi: 10.1093/ejcts/ezab253.
5
"Maximal" thymectomy for myasthenia gravis. Results.重症肌无力的“最大程度”胸腺切除术。结果
J Thorac Cardiovasc Surg. 1988 May;95(5):747-57.
6
Normalization of elevated CD4-/CD8- (double-negative) T cells after thymectomy parallels clinical remission in myasthenia gravis associated with thymic hyperplasia but not thymoma.胸腺切除术后,伴有胸腺增生而非胸腺瘤的重症肌无力患者,其升高的CD4-/CD8-(双阴性)T细胞的正常化与临床缓解平行。
Ann Neurol. 2000 Oct;48(4):603-8.
7
Factors predicting remission in thymectomized patients with acetylcholine receptor antibody-positive myasthenia gravis.预测乙酰胆碱受体抗体阳性的胸腺瘤切除术后重症肌无力患者缓解的因素。
Muscle Nerve. 2018 Dec;58(6):796-800. doi: 10.1002/mus.26300. Epub 2018 Nov 8.
8
Risk factors for developing post-thymectomy myasthenia gravis in patients with thymoma.胸腺瘤患者发生胸腺瘤切除术后重症肌无力的风险因素。
Muscle Nerve. 2021 Apr;63(4):531-537. doi: 10.1002/mus.27169. Epub 2021 Feb 15.
9
[Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients].[胸腺瘤性与非胸腺瘤性重症肌无力的胸腺切除术:46例患者队列分析]
Rev Neurol. 2020 Mar 16;70(6):213-219. doi: 10.33588/rn.7006.2019411.
10
Onset and Evolution of Clinically Apparent Myasthenia Gravis After Resection of Non-myasthenic Thymomas.非肌无力性胸腺瘤切除术后临床明显重症肌无力的发病与进展
Semin Thorac Cardiovasc Surg. 2018 Summer;30(2):222-227. doi: 10.1053/j.semtcvs.2018.02.027. Epub 2018 Mar 6.

引用本文的文献

1
Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment.多西他赛治疗后伴重症肌无力胸腺瘤潜在血清蛋白生物标志物的鉴定
Neurol Ther. 2023 Apr;12(2):559-570. doi: 10.1007/s40120-023-00442-3. Epub 2023 Feb 14.
2
Assessment of the risks of a myasthenic crisis after thymectomy in patients with myasthenia gravis: a systematic review and meta-analysis of 25 studies.评估胸腺瘤切除术后重症肌无力患者发生肌无力危象的风险:25 项研究的系统评价和荟萃分析。
J Cardiothorac Surg. 2020 Sep 29;15(1):270. doi: 10.1186/s13019-020-01320-x.

本文引用的文献

1
Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma.多西他赛联合顺铂化疗对转移性胸腺瘤重症肌无力患者的治疗潜力
Tohoku J Exp Med. 2017 Apr;241(4):281-286. doi: 10.1620/tjem.241.281.
2
Metastatic Thymoma-Associated Myasthenia Gravis: Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent.转移性胸腺瘤相关重症肌无力:对类固醇冲击疗法加免疫抑制剂反应良好。
Med Sci Monit. 2017 Mar 9;23:1217-1223. doi: 10.12659/msm.902442.
3
Docetaxel for the treatment of bladder cancer.多西他赛用于治疗膀胱癌。
Expert Opin Investig Drugs. 2015;24(12):1657-64. doi: 10.1517/13543784.2015.1109626. Epub 2015 Nov 4.
4
Myasthenia gravis: subgroup classification and therapeutic strategies.重症肌无力:亚组分类与治疗策略。
Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3.
5
Risk of diabetes mellitus among patients with myasthenia gravis.重症肌无力患者患糖尿病的风险。
Acta Neurol Scand. 2015 Aug;132(2):132-8. doi: 10.1111/ane.12374. Epub 2015 Jan 28.
6
The clinical absolute and relative scoring system-a quantitative scale measuring myasthenia gravis severity and outcome used in the traditional Chinese medicine.临床绝对和相对评分系统——一种用于中医测量重症肌无力严重程度和预后的定量量表。
Complement Ther Med. 2014 Oct;22(5):877-86. doi: 10.1016/j.ctim.2014.08.003. Epub 2014 Aug 18.
7
Prevalence of hypertension in china: a cross-sectional study.中国高血压患病率:一项横断面研究。
PLoS One. 2013 Jun 11;8(6):e65938. doi: 10.1371/journal.pone.0065938. Print 2013.
8
A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.一项多西他赛/顺铂诱导化疗治疗 Masaoka 分期 III/IV 胸腺上皮肿瘤的前瞻性 II 期试验。
J Thorac Oncol. 2013 Jul;8(7):959-66. doi: 10.1097/JTO.0b013e318292c41e.
9
The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes.不同亚型重症肌无力的发病机制中胸腺的不同作用。
Autoimmun Rev. 2013 Jul;12(9):875-84. doi: 10.1016/j.autrev.2013.03.007. Epub 2013 Mar 25.
10
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.吉非替尼对比顺铂联合多西他赛用于治疗表皮生长因子受体突变的非小细胞肺癌患者(WJTOG3405):一项开放标签、随机对照 3 期临床试验。
Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18.

多西他赛/顺铂疗法用于合并高血压/糖尿病的重症肌无力患者

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes.

作者信息

Qi Guoyan, Xue Yinping, Li Yongzhao, Yang Hongxia, Zhang Xiaojing

机构信息

No. 9 Fangbei Road, Chang'an District, Shijiangzhuang 050011, Hebei Province, China.

Center of Treatment of Myasthenia Gravis Hebei Province, First Hospital of Shijiazhuang, Shijiazhuang050011, China.

出版信息

Open Med (Wars). 2017 Dec 2;12:403-408. doi: 10.1515/med-2017-0058. eCollection 2017.

DOI:10.1515/med-2017-0058
PMID:29318185
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5757353/
Abstract

BACKGROUND

Therapeutic options for thymoma-associated myasthenia gravis (MG) patients complicated with hypertension and/or diabetes post thymectomy are often conventional steroids. As the prevalence of diabetes and hypertension globally increases, other therapeutic options for these patients are of great importance.

MATERIAL/METHODS: 9 patients with thymoma-associated MG complicated with hypertension and/or diabetes after thymectomy were administered 75 mg/m2 of docetaxel and 70 mg/m2 of cisplatin on day 1. The treatment could be repeated at 3-week intervals, ranging from 1 to 4 cycles according to the status of the patients. Therapeutic efficacy and side effects were evaluated.

RESULTS

2 patients were complicated with type 2 diabetes, 6 with hypertension, and 1 with both diabetes and hypertension. After docetaxel/cisplain therapy, the MG symptoms were markedly improved in all patients (2, complete remission; 3, basic remission; 3, marked improvement; 1, improvement). Acetylcholine receptor (AchR) antibody levels were decreased in 8 patients. Minor adverse effects were observed in 2 patients, 1 with Grade II gastrointestinal reaction, and the other with pulmonary infection.

CONCLUSION

Docetaxel plus cisplatin might be an effective therapeutic option for thymoma-associated MG patients complicated with hypertension /diabetes post thymectomy without worsening thymoma and hypertension / diabetes.

摘要

背景

胸腺瘤相关重症肌无力(MG)患者胸腺切除术后合并高血压和/或糖尿病,其治疗选择通常为传统类固醇药物。随着全球糖尿病和高血压患病率的上升,这些患者的其他治疗选择具有重要意义。

材料/方法:9例胸腺切除术后胸腺瘤相关MG合并高血压和/或糖尿病的患者在第1天接受75mg/m²多西他赛和70mg/m²顺铂治疗。治疗可每3周重复一次,根据患者情况进行1至4个周期。评估治疗效果和副作用。

结果

2例患者合并2型糖尿病,6例合并高血压,1例同时合并糖尿病和高血压。多西他赛/顺铂治疗后,所有患者的MG症状均明显改善(2例完全缓解;3例基本缓解;3例显著改善;1例改善)。8例患者的乙酰胆碱受体(AchR)抗体水平降低。2例患者出现轻微不良反应,1例为Ⅱ级胃肠道反应,另1例为肺部感染。

结论

多西他赛加顺铂可能是胸腺切除术后胸腺瘤相关MG合并高血压/糖尿病患者的有效治疗选择,且不会使胸腺瘤及高血压/糖尿病病情恶化。